Factory 99% Daclatasvir Powder CAS 1009119-64-5 Anti-Cancer Chemical Intermediate Daclatasvir

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A701
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Daclatasvir
• CAS: 1009119-64-5
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Anti-Cancer
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Daclatasvir
Appearance	White Powder
CAS NO.	1009119-64-5
MF	C40H50N8O6
Storage	Keep in a cool, dry, dark location

 

Daclatasvir is a potent NS5A inhibitor with broad-genotype coverage and high efficacy in combination therapy for the treatment of chronic HCV infection. Its improved tolerability makes it a valuable option for patients seeking to cure their HCV infection.

 

1. Treatment of HCV: Daclatasvir is primarily used in combination therapy for the treatment of chronic HCV infection. It is often prescribed in conjunction with other antiviral agents to enhance treatment efficacy.
2. Genotype Coverage: The drug is effective against multiple HCV genotypes, including genotype 1, which is particularly difficult to treat. This broad-genotype coverage makes daclatasvir a valuable option in a variety of clinical settings.
3. Pan-Genotypic Therapy:Daclatasvir can be used in pan-genotypic regimens, simplifying treatment protocols and reducing the need for genotype-specific therapies.

1. NS5A Inhibition: Daclatasvir functions by inhibiting the NS5A protein of HCV, which is essential for viral replication. By blocking this protein, daclatasvir disrupts the HCV lifecycle and prevents viral spread.
2. Increased Efficacy in Combination Therapy: When used in combination with other antiviral agents, daclatasvir enhances the overall efficacy of HCV treatment, leading to higher cure rates and lower relapse rates.
3. Improved Tolerability: Daclatasvir is generally well-tolerated, with a low incidence of serious adverse events. This improved tolerability contributes to better patient compliance and adherence to treatment protocols.